Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML

• Main Authors: Qing Ling (Author), Yutong Zhou (Author), Yu Qian (Author), Jiejing Qian (Author), Yi Zhang (Author), Jinghan Wang (Author), Yanan Zhu (Author), Yile Zhou (Author), Juying Wei (Author), Chunmei Yang (Author), Jie Sun (Author), Wenjuan Yu (Author), Jie Jin (Author), Xiang Zhang (Author)
• Format: Book
• Published: BMC, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract KMT2A-rearranged acute myeloid leukemia (KMT2Ar-AML) is an aggressive subtype of AML with poor response and prognosis. KMT2Ar-AML has been demonstrated to be sensitive to BCL2 inhibitor venetoclax (VEN), but these patients are unable to benefit from current VEN-based regimen (VEN plus azaci...